0.3029
price down icon1.05%   -0.0032
after-market Dopo l'orario di chiusura: .31 0.0071 +2.34%
loading
Precedente Chiudi:
$0.3061
Aprire:
$0.3084
Volume 24 ore:
2.35M
Relative Volume:
0.43
Capitalizzazione di mercato:
$37.75M
Reddito:
$36.86M
Utile/perdita netta:
$-171.67M
Rapporto P/E:
-0.2019
EPS:
-1.5
Flusso di cassa netto:
$-171.05M
1 W Prestazione:
-20.18%
1M Prestazione:
-40.41%
6M Prestazione:
-85.71%
1 anno Prestazione:
-92.87%
Intervallo 1D:
Value
$0.291
$0.3312
Intervallo di 1 settimana:
Value
$0.291
$0.3795
Portata 52W:
Value
$0.291
$4.44

Mersana Therapeutics Inc Stock (MRSN) Company Profile

Name
Nome
Mersana Therapeutics Inc
Name
Telefono
617-498-0020
Name
Indirizzo
840 MEMORIAL DRIVE, CAMBRIDGE
Name
Dipendente
102
Name
Cinguettio
@MersanaADC
Name
Prossima data di guadagno
2025-03-03
Name
Ultimi documenti SEC
Name
MRSN's Discussions on Twitter

Confronta MRSN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
MRSN
Mersana Therapeutics Inc
0.3029 37.75M 36.86M -171.67M -171.05M -1.50
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-06 Iniziato William Blair Outperform
2024-11-15 Ripresa Citigroup Buy
2024-03-19 Aggiornamento JP Morgan Underweight → Neutral
2024-02-29 Aggiornamento BTIG Research Neutral → Buy
2024-02-29 Aggiornamento Guggenheim Neutral → Buy
2024-02-29 Aggiornamento Wedbush Neutral → Outperform
2023-12-04 Aggiornamento Citigroup Neutral → Buy
2023-07-28 Downgrade Robert W. Baird Outperform → Neutral
2023-07-27 Downgrade BTIG Research Buy → Neutral
2023-07-27 Downgrade Citigroup Buy → Neutral
2023-07-27 Downgrade Guggenheim Buy → Neutral
2023-07-27 Downgrade JP Morgan Neutral → Underweight
2023-07-27 Downgrade Truist Buy → Hold
2023-07-27 Downgrade Wedbush Outperform → Neutral
2023-06-16 Downgrade JP Morgan Overweight → Neutral
2023-06-15 Iniziato Guggenheim Buy
2023-03-16 Aggiornamento JP Morgan Neutral → Overweight
2023-01-20 Iniziato Citigroup Buy
2022-11-21 Iniziato Truist Buy
2021-10-15 Ripresa BTIG Research Buy
2021-08-30 Iniziato H.C. Wainwright Buy
2021-03-31 Iniziato Credit Suisse Neutral
2020-12-03 Iniziato Stifel Buy
2020-09-29 Ripresa JP Morgan Neutral
2020-04-29 Iniziato BTIG Research Buy
2020-01-21 Reiterato H.C. Wainwright Buy
2019-03-11 Downgrade JP Morgan Neutral → Underweight
2018-11-14 Aggiornamento Leerink Partners Mkt Perform → Outperform
2018-05-08 Iniziato Robert W. Baird Outperform
2018-03-19 Downgrade JP Morgan Overweight → Neutral
Mostra tutto

Mersana Therapeutics Inc Borsa (MRSN) Ultime notizie

pulisher
04:17 AM

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

04:17 AM
pulisher
04:05 AM

Mersana Strengthens Team with Strategic 26,790-Share RSU Grant to New Hire - Stock Titan

04:05 AM
pulisher
Apr 02, 2025

When Would Be The Best Time To Buy Mersana Therapeutics Inc (NASDAQ: MRSN) Stock? - stocksregister.com

Apr 02, 2025
pulisher
Apr 01, 2025

Mersana Therapeutics Announces Upcoming Oral Presentation - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

FDA Fast-Tracked Breast Cancer Drug Shows Promise: Key Clinical Data Coming at ESMO 2025 - Stock Titan

Apr 01, 2025
pulisher
Mar 28, 2025

Critical Contrast: Mersana Therapeutics (NASDAQ:MRSN) & Opus Genetics (NASDAQ:IRD) - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

MRSN stock plunges to 52-week low of $0.37 amid market challenges - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

MRSN stock plunges to 52-week low of $0.37 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough - simplywall.st

Mar 27, 2025
pulisher
Mar 20, 2025

MRSN stock touches 52-week low at $0.43 amid sharp decline - Investing.com India

Mar 20, 2025
pulisher
Mar 13, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Mar 13, 2025
pulisher
Mar 11, 2025

MRSN stock plunges to 52-week low of $0.45 amid market challenges - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Mersana at Leerink Global Healthcare Conference: Strategic ADC Insights By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 11, 2025

MRSN stock plunges to 52-week low of $0.45 amid market challenges By Investing.com - Investing.com South Africa

Mar 11, 2025
pulisher
Mar 10, 2025

Q1 EPS Estimates for Mersana Therapeutics Lowered by Wedbush - MarketBeat

Mar 10, 2025
pulisher
Mar 08, 2025

Industry Analysts Just Made A Meaningful Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts - Simply Wall St

Mar 08, 2025
pulisher
Mar 07, 2025

Mersana Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Brokers Issue Forecasts for MRSN Q1 Earnings - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Q1 EPS Estimate for Mersana Therapeutics Reduced by Analyst - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Earnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance

Mar 06, 2025
pulisher
Mar 05, 2025

Industry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts - Yahoo Finance

Mar 05, 2025
pulisher
Mar 04, 2025

Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 04, 2025
pulisher
Mar 04, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 04, 2025
pulisher
Mar 04, 2025

Mersana Therapeutics (NASDAQ:MRSN) Receives “Outperform” Rating from Wedbush - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada

Mar 04, 2025
pulisher
Mar 04, 2025

Mersana Therapeutics’ Viability in Question Amidst Persistent Financial Losses and Funding Challenges - TipRanks

Mar 04, 2025
pulisher
Mar 03, 2025

Mersana Therapeutics Reports Progress and Financial Results - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Mersana Therapeutics’ Earnings Call Highlights Clinical Progress and Financial Gains - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Earnings call transcript: Mersana Therapeutics Q4 2024 beats EPS forecast By Investing.com - Investing.com Canada

Mar 03, 2025
pulisher
Mar 03, 2025

Earnings call transcript: Mersana Therapeutics Q4 2024 beats EPS forecast - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

Mersana Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 03, 2025
pulisher
Mar 03, 2025

Mersana Therapeutics reports Q4 EPS (11c), consensus (17c) - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Mersana Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 03, 2025
pulisher
Mar 03, 2025

Mersana Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada

Mar 03, 2025
pulisher
Mar 03, 2025

Mersana Therapeutics Announces Positive Phase 1 Clinical Data - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

Mersana's ADC Pipeline Advances: FDA Fast Track Designation as Q4 Losses Narrow - StockTitan

Mar 03, 2025
pulisher
Mar 02, 2025

What To Expect From Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings - GuruFocus.com

Mar 02, 2025
pulisher
Mar 01, 2025

MRSN stock touches 52-week low at $0.49 amid sharp annual decline - Investing.com Australia

Mar 01, 2025
pulisher
Mar 01, 2025

William Blair starts Mersana stock with Outperform rating - MSN

Mar 01, 2025
pulisher
Feb 28, 2025

Mersana Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Mersana Therapeutics faces Nasdaq delisting over share price - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

MRSN stock touches 52-week low at $0.49 amid sharp annual decline By Investing.com - Investing.com South Africa

Feb 28, 2025

Mersana Therapeutics Inc Azioni (MRSN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Capitalizzazione:     |  Volume (24 ore):